For research use only. Not for therapeutic Use.
RET-IN-7 demonstrates potent in vitro RET kinase inhibition and robust in vivo efficacy in RET-driven tumor xenografts upon multiday dosing in mice.
Catalog Number | I045219 |
CAS Number | 2763386-05-4 |
Synonyms | methyl N-[4-[4-amino-5-(5-amino-4-chloro-2-fluorophenyl)pyrrolo[2,3-d]pyrimidin-7-yl]-1-bicyclo[2.2.2]octanyl]carbamate |
Molecular Formula | C22H24ClFN6O2 |
Purity | ≥95% |
InChI | InChI=1S/C22H24ClFN6O2/c1-32-20(31)29-21-2-5-22(6-3-21,7-4-21)30-10-13(17-18(26)27-11-28-19(17)30)12-8-16(25)14(23)9-15(12)24/h8-11H,2-7,25H2,1H3,(H,29,31)(H2,26,27,28) |
InChIKey | FJTQBVRKZLEDPK-UHFFFAOYSA-N |
SMILES | COC(=O)NC12CCC(CC1)(CC2)N3C=C(C4=C(N=CN=C43)N)C5=CC(=C(C=C5F)Cl)N |
Reference | [1]. Mathison CJN, et al. Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-d]pyrimidine RET Inhibitors. ACS Med Chem Lett. 2021 Nov 6;12(12):1912-1919. |